AQR Capital Management
RAPP

AQR Capital Management’s Rapport Therapeutics RAPP Stock Holding History

AQR Capital Management’s Portfolio RAPP Stock Details RAPP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.1M Buy
26,454
+944
+4% +$34.7K ﹤0.01% 2954
2026
Q1 		$798K Buy
25,510
+4,632
+22% +$130K ﹤0.01% 2893
2025
Q4 		$633K Buy
20,878
+256
+1% +$7.08K ﹤0.01% 2793
2025
Q3 		$612K Buy
20,622
+3,650
+22% +$65.1K ﹤0.01% 2706
2025
Q2 		$193K Buy
+16,972
New +$180K ﹤0.01% 3058

Other funds holding RAPP

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
TGV
TRV GP V Boston, Massachusetts $498M AUM 267.53% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

AQR Capital Management's RAPP Position: Q2 2026 in Review

AQR Capital Management increased its Rapport Therapeutics (RAPP) stake by 3.7% in Q2 2026, buying an estimated $34.7K and bringing the position to 26,454 shares worth $1.1M. The position accounts for ﹤0.01% of the portfolio, ranked #2954.

AQR Capital Management first reported a position in RAPP in Q2 2025 and has held it in 5 quarters since. 161 funds tracked by Wall St. Rank hold RAPP as of Q2 2026.

  • AQR Capital Management held 26,454 shares of Rapport Therapeutics worth $1.1M as of Q2 2026.
  • AQR Capital Management bought 944 Rapport Therapeutics shares in Q2 2026, an estimated $34.7K.
  • Rapport Therapeutics made up ﹤0.01% of AQR Capital Management's portfolio in Q2 2026, its #2954 holding.
  • AQR Capital Management first reported a position in Rapport Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • 161 funds tracked by Wall St. Rank held Rapport Therapeutics as of Q2 2026.

Based on AQR Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.